<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1211246206
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Mictonorm
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPIVERINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        36.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROTTENDORF PHARMA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROTTENDORF PHARMA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Labatec- Pharma S.A
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BD06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mictonorm 5 mg is used for the treatment of adults and children who have difﬁculty in controlling their bladders due to bladder overactivity or, who have problems with the spinal cord. Mictonorm 5 mg contains the active substance Propiverine hydrochloride. This substance prevents the bladder from contracting and increases the amount that the bladder can hold. Mictonorm 5 mg is used to treat the symptoms of overactive bladder.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Mictonorm 5 mg if</strong></p><p>You or your child are allergic (hypersensitive) to propiverine hydrochloride or any of the other ingredients of this medicine (listed in section 6)</p><p><strong>Do not take Mictonorm 5 mg if you or your child have</strong></p><p>&middot; &nbsp;Obstruction of the bowel</p><p>&middot; &nbsp;Obstruction to the bladder outlet (difﬁculty in passing urine)</p><p>&middot; &nbsp;Myasthenia gravis (a disease causing muscle weakness)</p><p>&middot; &nbsp;A loss of function of the muscles controlling your bowel movements (intestinal atony)</p><p>&middot; &nbsp;Severe inﬂammation of the bowel (ulcerative colitis) that may lead to diarrhea containing blood and mucus and abdominal</p><p>&nbsp;pains</p><p>&middot; &nbsp;Toxic megacolon (a condition involving enlargement of the bowel)</p><p>&middot; &nbsp;Increased pressure in the eye (uncontrolled angle closure glaucoma)</p><p>&middot; &nbsp;Moderate or severe liver disease</p><p>&middot; &nbsp;Fast or irregular heartbeat</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist or nurse before taking Mictonorm 5 mg if you or your child have:</p><p>&middot; &nbsp;Damage to the nerves that control blood pressure, heart rate, bowel and bladder movement and other bodily functions (autonomic neuropathy)</p><p>&middot; &nbsp;Liver problems</p><p>&middot; &nbsp;Kidney problems</p><p>&middot; &nbsp;Severe heart failure</p><p>&middot; &nbsp;Enlargement of the prostate gland</p><p>&middot; &nbsp;Recurrent urinary tract infection</p><p>&middot; &nbsp;Tumors of the urinary tract</p><p>&middot; &nbsp;Glaucoma</p><p>&middot; &nbsp;Heartburn and indigestion due to back ﬂow of gastric juice into the throat (hiatus hernia with reﬂux esophagitis)</p><p>&middot; &nbsp;Irregular heartbeat</p><p>&middot; &nbsp;Fast heartbeat</p><p>If you or your child suffer from any of these conditions, contact your doctor. He will tell you what to do.</p><p><strong>Children</strong></p><p>The treatment of children with symptoms of overactive bladder should not begin before an age of 5 years and is only recommended in addition with behavior modiﬁcation, like voiding and drinking habits. The treatment of children with problems with the spinal cord may be started before an age of 5 years. The treatment of children younger than 1 year is not recommended due to a lack of data.</p><p><strong>Other medicines and Mictonorm 5 mg</strong></p><p>Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any of the following medicines as they may interact with Mictonorm 5 mg.</p><p>&middot; Antidepressants (e.g. imipramine, clomipramine, amitriptyline)</p><p>&middot; Sleeping tablets (e.g. benzodiazepines)</p><p>&middot; Anticholinergics taken by mouth or injection (usually used to treat asthma, stomach cramps, eye problems or urinary incontinence)</p><p>&middot; Amantadine (used to treat ﬂu and Parkinson&rsquo;s disease)</p><p>&middot; Neuroleptics such as promazine, olanzapine, quetiapine (drugs used to treat psychotic disorders like schizophrenia and anxiety)</p><p>&middot; Beta stimulants (drugs used to treat asthma)</p><p>&middot; Cholinergics (e.g. carbachol and pilocarpine)</p><p>&middot; Isoniazid (a treatment for tuberculosis)</p><p>&middot; Metoclopramide (used to treat nausea and vomiting)</p><p>&middot; Concomitant treatment with methimazole (used to treat hyperfunction of the thyroid gland) and medicines used to treat fungal diseases (e.g. ketoconazole, itraconazole)</p><p>Nevertheless, it may still be all right for you or your child to take Mictonorm 5 mg. Your doctor will be able to decide what is suitable for you or your child.</p><p>Please tell your doctor or pharmacist if you or your child are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Do not take Mictonorm 5 mg if you are pregnant, likely to become pregnant or are breast-feeding.</p><p><strong>Driving and using machines</strong></p><p>Mictonorm 5 mg can sometimes cause sleepiness and blurred vision. You should not drive or operate machinery until you are sure you are not affected.</p><p><strong>Mictonorm 5 mg contains glucose, lactose, and sucrose (sugars)</strong></p><p>If you have been told by your doctor that you or your child have intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Use in children and adolescents</strong></p><p>The recommended dose is an average daily dose of 0.8 mg/kg body weight given in two or three single doses.</p><p><strong>The recommended dose is</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:189px"><tbody><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p><strong>Mictonorm 5 mg</strong></p></td></tr><tr><td><p>12 &ndash; 16</p></td><td><p>1 &ndash; 0 &ndash; 1</p></td></tr><tr><td><p>17 &ndash; 22</p></td><td><p>1 &ndash; 1 &ndash; 1</p></td></tr><tr><td><p>23 &ndash; 28</p></td><td><p>2 &ndash; 0 &ndash; 2</p></td></tr><tr><td><p>29 &ndash; 34</p></td><td><p>2 &ndash; 1 &ndash; 2</p></td></tr><tr><td><p>&ge; 35</p></td><td><p>2 &ndash; 2 &ndash; 2</p><p>or 3 &ndash; 0 &ndash; 3</p></td></tr></tbody></table><p>In children or adolescents with a body weight over 35 kg the maximum dose is the same as the standard adult dose of 15 mg twice daily (2 x 3 Mictonorm 5 mg).</p><p><strong>Adults and the elderly:</strong></p><p>As a standard dose for overactive bladder, 15 mg propiverine hydrochloride twice daily is recommended; an increase to three times daily is possible. Some patients may respond to a dose as low as 15 mg daily (3 x 5 mg).</p><p><strong>For neurogenic detrusor overactivity</strong></p><p>A dose of 15 mg propiverine hydrochloride three times daily is recommended. The maximum recommended daily dose is 45 mg.</p><p><strong>Method of administration:</strong></p><p>Take your tablets at the same times each day.The tablets should be swallowed whole with water before meals.</p><p><strong>If you or your child take more Mictonorm 5 mg than you should</strong></p><p>If you or your child have accidentally taken more than your prescribed dose, contact your nearest casualty department or tell your doctor or pharmacist immediately. Remember to take the pack and any remaining tablets with you.</p><p><strong>If you forget to take Mictonorm 5 mg</strong></p><p>Do not worry. Simply leave out that dose completely. Then take your next dose at the right time. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>All medicines can cause allergic reactions although serious allergic reactions are very rare.</p><p>The following symptoms are ﬁrst signs for such reactions:</p><p>&middot; Any sudden wheeziness, difﬁculty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</p><p>&middot; Peeling and blistering of the skin, mouth, eyes and genitals.</p><p>&middot; Rash affecting your whole body.</p><p>If you or your child get any of these symptoms during treatment, you should stop taking the tablets and contact your doctor immediately.</p><p>You or your child might suffer an acute attack of glaucoma. If you have been seeing colored rings around lights or if you should develop severe pain in and around eye <strong>you should seek medical attention urgently.</strong></p><p>The following side effects have been reported:</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>Dry mouth.</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>Abnormal vision and difﬁculty in focusing, fatigue, headache, abdominal pain, indigestion, constipation.</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>Feeling sick and vomiting, dizziness, trembling (tremor), inability to empty the bladder (urinary retention), ﬂushing, altered sense of taste, decreased blood pressure with drowsiness, itching, difﬁculty in passing urine.</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>Rash.</p><p>Faster heartbeat.</p><p><strong>Very Rare (may affect up to 1 in 10,000 people)</strong></p><p>Feeling your heartbeat, restlessness and confusion.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>Sensing things that are not real (hallucinations).</p><p>Speech disorder.</p><p><strong>Additional side effects in children and adolescents</strong></p><p>In addition, in studies with children the following undesirable effects were observed: loss of appetite, sleep disturbance and impaired concentration.</p><p>All possible side effects are transient and recede after a dose reduction or termination of the therapy after maximum 1-4 days.</p><p>During long-term therapy hepatic enzymes should be monitored, because reversible changes of liver enzymes might occur in rare cases.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaﬂet. Any suspected or adverse event on this product should be reported to drugsafety@labatec.com.</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Keep this medicine out of sight and reach of children.</p><p>&middot; Do not store the blister pack above 30&deg;C.</p><p>&middot; Do not use this medicine after the expiry date which is stated on the carton.</p><p>&middot; The expiry date refers to the last day of that month.</p><p>&middot; Do not throw away any medicines via wastewater or household waste.</p><p>&middot; Ask your pharmacist how to throw away medicines you no longer use.</p><p>&middot; These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is propiverine hydrochloride. Each coated tablet contains 5 mg of propiverine hydrochloride.</p><p>The other ingredients are lactose monohydrate, cellulose powdered, magnesium stearate, sucrose, talc, kaolin heavy, calcium carbonate, titanium dioxide (E171), acacia spray dried, colloidal anhydrous silica, macrogol 6000, glucose monohydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Available in pharmacy with medical prescription.
Mictonorm 5 mg are white, lenticular coated tablets are available in boxes of 7 (7's Blister x 1) and 28 (14's Blister x 2) coated tablets in blister packs.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer:</p><p>Rottendorf Pharma GmbH, Ostenfelder Stra&szlig;e 51 &ndash; 61, 59320 Ennigerloh, Germany</p><p>Batch Releaser:</p><p>APOGEPHA Arzneimittel GmbH, Kyffh&auml;userstra&szlig;e 27, 01309 Dresden, Germany</p><p>Marketing Authorization Holder</p><p>Labatec Pharma SA, 1217 Meyrin (Geneva), Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in (12/2022)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ﯾﺳﺗﺧدم (ميكتونورم 5 ملغ)ﻟﻌﻼج اﻷﺷﺧﺎص اﻟذﯾن ﯾﺟدون ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﺣﻛم ﻓﻲ اﻟﻣﺛﺎﻧﺔ ﺑﺳﺑب ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ أو الذين يعانون من مشاكل في النخاع الشوكي. ﯾﺣﺗوي (ميكتونورم 5 ملغ)ﻋﻠﻰ اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ﺑروﺑﯾﻔﯾرﯾن ھﯾدروﻛﻠورﯾد. ھذه اﻟﻣﺎدة ﺗﻣﻧﻊ اﻟﻣﺛﺎﻧﺔ ﻣن اﻻﻧﻘﺑﺎض وﺗزﯾد ﻣن اﻟﻛﻣﯾﺔ اﻟﺗﻲ ﯾﻣﻛن أن ﺗﺣﺗﻔظ ﺑﮭﺎ اﻟﻣﺛﺎﻧﺔ. ﯾﺳﺗﺧدم (ميكتونورم 5 ملغ)ﻟﻌﻼج أﻋراض ﻓرط ﻧﺷﺎط اﻟﻣﺛﺎﻧﺔ. إﻧﮭﺎ ﻛﺑﺳوﻟﺔ ﻣﻌدﻟﺔ اﻟﻣﻔﻌول ﻻ ﺗﺣﺗﺎج إﻟﻰ ﺗﻧﺎوﻟﮭﺎ إﻻ ﻣرة واﺣدة ﻓﻲ اﻟﯾوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول (ميكتونورم 5 ملغ)إذا:-</strong></p><p dir="RTL">ﻛﻧت أنت أو طفلك تعانيان ﻣن ﺣﺳاﺳﯾﺔ ﺗﺟﺎه ﺑروﺑﯾﻔﯾرﯾن ھﯾدروﻛﻠورﯾد أو أي ﻣن اﻟﻣﻛوﻧﺎت اﻷﺧرى ﻟﮭذا اﻟدواء اﻟﻣدرﺟﺔ ﻓﻲ اﻟﻘﺳم 6</p><p dir="RTL"><strong>لا تتناول انت أو طفلك (ميكتونورم 5 ملغ):-</strong></p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻧﺳداد ﻓﻲ اﻷﻣﻌﺎء.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻧﺳداد ﻓﻲ ﻣﺧرج اﻟﻣﺛﺎﻧﺔ )ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﺑول(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﻟوھن اﻟﻌﺿﻠﻲ اﻟﺷدﯾد )ﻣرض ﯾﺳﺑب ﺿﻌف اﻟﻌﺿﻼت(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻓﻘدان وظﯾﻔﺔ اﻟﻌﺿﻼت اﻟﺗﻲ ﺗﺗﺣﻛم ﻓﻲ ﺣرﻛﺎت اﻷﻣﻌﺎء )وﻧﻰ اﻷﻣﻌﺎء(.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك اﻟﺗﮭﺎب ﺷدﯾد ﻓﻲ اﻷﻣﻌﺎء )اﻟﺗﮭﺎب اﻟﻘوﻟون اﻟﺗﻘرﺣﻲ) اﻟذي ﻗد ﯾؤدي إﻟﻰ إﺳﮭﺎل ﯾﺣﺗوي ﻋﻠﻰ دم&nbsp; وﻣﺧﺎط وآﻻم ﻓﻲ اﻟﺑطن.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺗﺿﺧم اﻟﻘوﻟون اﻟﺳﺎم )ﺣﺎﻟﺔ ﺗﺷﻣل ﺗﺿﺧم اﻷﻣﻌﺎء(.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺿﻐط ﻣﺗزاﯾد ﻓﻲ اﻟﻌﯾن) زرق اﻟﻌﯾن ﻏﯾر اﻟﻣﻧﺿﺑط(.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻣرض ﻛﺑدي ﻣﺗوﺳط أو ﺷدﯾد.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺿرﺑﺎت ﻗﻠب ﺳرﯾﻌﺔ أو ﻏﯾر ﻣﻧﺗظﻣﺔ.</p><p dir="RTL"><strong>المحاذير واﻹﺣﺗﯾﺎطﺎت</strong></p><p dir="RTL">ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ ﻗﺑل ﺗﻧﺎول (ميكتونورم 5 ملغ)</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺗﻠف ﻓﻲ اﻷﻋﺻﺎب اﻟﺗﻲ ﺗﺗﺣﻛم ﻓﻲ ﺿﻐط اﻟدم وﻣﻌدل ﺿرﺑﺎت اﻟﻘﻠب وﺣرﻛﺔ اﻷﻣﻌﺎء واﻟﻣﺛﺎﻧﺔ وﻏﯾرھﺎ ﻣن وظﺎﺋف اﻟﺟﺳم (اﻻﻋﺗﻼل اﻟﻌﺻﺑﻲ اﻟﻼإرادي).</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﺑد.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﻠﻰ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻗﺻور ﺣﺎد ﻓﻲ اﻟﻘﻠب.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﺗﺿﺧم ﻓﻲ ﻏدة اﻟﺑروﺳﺗﺎﺗﺎ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻋدوى ﻣﺗﻛررة ﻓﻲ اﻟﻣﺳﺎﻟك اﻟﺑوﻟﯾﺔ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك أورام ﻓﻲ اﻟﻣﺳﺎﻟك اﻟﺑوﻟﯾﺔ.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك زرق اﻟﻌﯾن.</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣرﻗﺔ ﻓﻲ اﻟﻣﻌدة وﻋﺳر اﻟﮭﺿم ﺑﺳﺑب اﻟﺗدﻓق اﻟﻌﻛﺳﻲ ﻟﻌﻌﺻﺎرة اﻟﻣﻌدة إﻟﻰ اﻟﺣﻠق (ﻓﺗق ﻓﺟوة ﻣﻊ اﻟﺗﮭﺎب اﻟﻣريء اﻻرﺗﺟﺎﻋﻲ).</p><p dir="RTL">&middot; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻋدم اﻧﺗظﺎم ﻓﻲ ﺿرﺑﺎت اﻟﻘﻠب.</p><p dir="RTL">&middot; إذا ﻛﺎن ﻟدﯾك ﺿرﺑﺎت ﻗﻠب ﺳرﯾﻌﺔ.</p><p dir="RTL">إذا كنت تعاني من أي من هذه الحالات، اتصل بطبيبك سيخبرك ماذا تفعل.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">یجب ألا یبدأ علاج الأطفال الذین یعانون من أعراض فرط نشاط المثانة قبل سن 5 سنوات ویوصى بھ فقط بالإضافة إلى تعدیل السلوك ، مثل عادات التبول والشرب. قد یبدأ علاج الأطفال الذین یعانون من مشاكل في النخاع الشوكي قبل سن 5 سنوات. لا یُنصح بمعالجة الأطفال الذین تقل أعمارھم عن سنة واحدة بسبب نقص البیانات.</p><p dir="RTL"><strong>الأدوﯾﺔ اﻷﺧرى و (ميكتونورم 5 ملغ)</strong></p><p dir="RTL">أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرًا أو ﻗد ﺗﺗﻧﺎول أﯾًﺎ ﻣن اﻷدوﯾﺔ اﻟﺗﺎﻟﯾﺔ ﻷﻧﮭﺎ ﻗد ﺗﺗﻔﺎﻋل ﻣﻊ (ميكتونورم 5 ملغ)</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻻﻛﺗﺋﺎب (ﻣﺛل إﯾﻣﯾﺑراﻣﯾن ، ﻛﻠوﻣﯾﺑراﻣﯾن ، أﻣﯾﺗرﯾﺑﺗﯾﻠﯾن).</p><p dir="RTL">&middot; أﻗراص اﻟﻧوم (ﻣﺛل اﻟﺑﻧزودﯾﺎزﯾﺑﯾﻧﺎت).</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻟﻛوﻟﯾن اﻟﺗﻲ ﺗؤﺧذ ﻋن طرﯾق اﻟﻔم أو اﻟﺣﻘن (ﺗﺳﺗﺧدم ﻋﺎدة ﻟﻌﻼج اﻟرﺑو ، ﺗﻘﻠﺻﺎت اﻟﻣﻌدة ﻣﺷﺎﻛل اﻟﻌﯾن أو ﺳﻠس اﻟﺑول).</p><p dir="RTL">&middot; أﻣﺎﻧﺗﺎدﯾن (ﯾﺳﺗﺧدم ﻟﻌﻼج اﻹﻧﻔﻠوﻧزا وﻣرض ﺑﺎرﻛﻧﺳون).</p><p dir="RTL">&middot; ﻣﺿﺎدات اﻟذھﺎن ﻣﺛل ﺑروﻣﺎزﯾن ، أوﻻﻧزاﺑﯾن ، ﻛﯾﺗﯾﺎﺑﯾن (أدوﯾﺔ ﺗﺳﺗﺧدم ﻟﻌﻼج اﻻﺿطراﺑﺎت اﻟذھﺎﻧﯾﺔ ﻣﺛل اﻟﻔﺻﺎم واﻟﻘﻠق).</p><p dir="RTL">&middot; ﻣﻧﺑﮭﺎت ﺑﯾﺗﺎ (أدوﯾﺔ ﺗﺳﺗﺧدم ﻟﻌﻼج اﻟرﺑو).</p><p dir="RTL">&middot; اﻟﻛوﻟﯾﻧﺎت (ﻛﺎرﺑﺎﻛول وﺑﯾﻠوﻛﺎرﺑﯾن).</p><p dir="RTL">&middot; أﯾزوﻧﯾﺎزﯾد (ﻋﻼج ﻟﻣرض اﻟﺳل).</p><p dir="RTL">&middot; ﻣﯾﺗوﻛﻠوﺑراﻣﯾد (ﯾﺳﺗﺧدم ﻟﻌﻼج اﻟﻐﺛﯾﺎن واﻟﻘﻲء).</p><p dir="RTL">&middot; اﻟﻌﻼج اﻟﻣﺗزاﻣن ﻣﻊ اﻟﻣﯾﺛﯾﻣﺎزول (اﻟذي ﯾﺳﺗﺧدم ﻟﻌﻼج ﻓرط ﻧﺷﺎط اﻟﻐدة اﻟدرﻗﯾﺔ) واﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻟﻌﻼج اﻷﻣراض اﻟﻔطرﯾﺔ (ﻣﺛل ﻛﯾﺗوﻛوﻧﺎزول ، إﯾﺗراﻛوﻧﺎزول).</p><p dir="RTL">وﻣﻊ ذﻟك، ﻗد ﯾﻛون ﻣن اﻟﻣﻧﺎﺳب ﻟك أن ﺗﺄﺧذ (ميكتونورم 5 ملغ) ﺳﯾﻛون طﺑﯾﺑك ﻗﺎدرًا ﻋﻠﻰ ﺗﺣدﯾد ﻣﺎ ھو ﻣﻧﺎﺳب ﻟك.</p><p dir="RTL">ﯾرﺟﻰ إﺧﺑﺎر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻣؤﺧرًا أي أدوﯾﺔ أﺧرى، ﺑﻣﺎ ﻓﻲ ذﻟك اﻷدوﯾﺔ اﻟﺗﻲ ﺗم اﻟﺣﺻول ﻋﻠﯾﮭﺎ ﺑدون وﺻﻔﺔ طﺑﯾﺔ.</p><p dir="RTL"><strong>الحمل واﻟرﺿﺎﻋﺔ واﻟﺧﺻوﺑﺔ</strong></p><p dir="RTL">إذا ﻛﻧت ﺣﺎﻣﻼ أو ﻣرﺿﻌﺔ ، ﺗﻌﺗﻘدﯾن أﻧك ﺣﺎﻣل أو ﺗﺧططﯾن ﻹﻧﺟﺎب طﻔل، اﺳﺄﻟﻲ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻣﺷورة ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.</p><p dir="RTL">ﻻ ﺗﺄﺧذي (ميكتونورم 5 ملغ)إذا ﻛﻧت ﺣﺎﻣﻼً أو ﻣن اﻟﻣﺣﺗﻣل أن ﺗﺻﺑﺣﻲ ﺣﺎﻣﻼً أو ﻣرﺿﻌﺔ.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ﯾﻣﻛن أن ﯾﺳﺑب (ميكتونورم 5 ملغ)أﺣﯾﺎﻧﺎ اﻟﻧﻌﺎس وﻋدم وﺿوح اﻟرؤﯾﺔ. ﻻ ﯾﺟوز ﻟك اﻟﻘﯾﺎدة أو ﺗﺷﻐﯾل اﻵﻻت ﺣﺗﻰ ﺗﺗﺄﻛد ﻣن ﻋدم ﺗﺄﺛرك.</p><p dir="RTL"><strong>يحتوي (ميكتونورم 5 ملغ)ﻋﻠﻰ ﺳﻛر الجلوكوز واﻟﻼﻛﺗوز والسكروز (السكريات)</strong></p><p dir="RTL">إذا أﺧﺑرك طﺑﯾﺑك أﻧك ﻻ ﺗﺗﺣﻣل ﺑﻌض اﻟﺳﻛرﯾﺎت ، ﻓﺎﺗﺻل ﺑطﺑﯾﺑك ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﺣرص داﺋﻣًﺎ ﻋﻠﻰ ﺗﻧﺎول ھذا اﻟدواء ﺗﻣﺎﻣًﺎ ﻛﻣﺎ أﺧﺑرك طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ. اﺳﺗﺷر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻟم ﺗﻛن ﻣﺗﺄﻛدًا.</p><p><strong>الاستخدام في الأطفال والمراهقين:</strong></p><p dir="RTL">الجرعة الموصى بھا ھي جرعة یومیة متوسطة تبلغ 0.8 ملغ /كجم من وزن الجسم تعطى في جرعتین أو ثلاث جرعات مفردة.</p><p dir="RTL">الجرعة الموصي بھا ھي:</p><table border="1" cellspacing="0" cellpadding="0" style="width:189px"><tbody><tr><td><p>وزن الجسم (كجم)</p></td><td><p>ميكتونورم 5 ملغ</p></td></tr><tr><td><p>12-16</p></td><td><p>1-0-1</p></td></tr><tr><td><p>17-22</p></td><td><p>1-1-1</p></td></tr><tr><td><p>23-28</p></td><td><p>2-0-2</p></td></tr><tr><td><p>29-34</p></td><td><p>2-1-2</p></td></tr><tr><td><p>&nbsp;&ge; 35</p></td><td><p>2-2-2</p><p>إو 3-0-3</p></td></tr></tbody></table><p dir="RTL">في الأطفال أو المراھقین الذین یزید وزن جسمھم عن 35 كجم، تكون الجرعة القصوى ھي نفس جرعة البالغین القیاسیة البالغة 15 ملغ مرتين يوميا (2 &times; 3 ميكتونورم 5 ملغ).</p><p dir="RTL">الكبار وكبار السن:</p><p dir="RTL">كجرعة قیاسیة لفرط نشاط المثانة ، یوصى باستخدام 15 ملغ من ھیدروكلورید البروبفیرین مرتین یومیًا ؛ یمكن زیادة ذلك إلى ثلاث مرات یومیًا. قد یستجیب بعض المرضى لجرعة منخفضة تصل إلى 15 ملغ يومياً (3 &times; 5 ملغ)</p><p dir="RTL">بالنسبة لفرط نشاط النافزات العصبیة ، یوصى بجرعة 15 ملغ من البروبفیرین ھیدروكلورید ثلاث مرات یومیًا. الجرعة الیومیة القصوى الموصى بھا ھي 45 ملغ.</p><p><strong>طريقة اﻻﺳﺗﻌﻣﺎل:</strong></p><p dir="RTL">تناول أقراصك في نفس الأوقات كل یوم. یجب ابتلاع الأقراص كاملة بالماء قبل الوجبات.</p><p><strong>إذا ﺗﻧﺎوﻟت (ميكتونورم 5 ملغ)أﻛﺛر ﻣﻣﺎ ﯾﺟب</strong></p><p dir="RTL">إذا ﺗﻧﺎوﻟت ﺑﺎﻟﺧطﺄ أﻛﺛر ﻣن اﻟﺟرﻋﺔ اﻟﻣوﺻوﻓﺔ ﻟك ، ﻓﺎﺗﺻل ﺑﺄﻗرب ﻗﺳم إﺻﺎﺑﺔ أو أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻋﻠﻰ اﻟﻔور. ﺗذﻛر أن ﺗﺄﺧذ اﻟﻌﻠﺑﺔ وأي ﻛﺑﺳوﻻت ﻣﺗﺑﻘﯾﺔ ﻣﻌك. ﯾﻣﻛن أن ﺗﺳﺑب اﻟﺟرﻋﺔ اﻟزاﺋدة أﻋراﺿًﺎ ﻣﺛل اﻷرق واﻟدوار واﺿطراﺑﺎت ﻓﻲ اﻟﻛﻼم واﻟرؤﯾﺔ وﺿﻌف اﻟﻌﺿﻼت وﺟﻔﺎف اﻟﻔم وﺳرﻋﺔ ﺿرﺑﺎت اﻟﻘﻠب وﻣﺷﺎﻛل اﻟﺗﺑول.</p><p><strong>إذا ﻧﺳﯾت أن ﺗﺄﺧذ (ميكتونورم 5 ملغ)</strong></p><p dir="RTL">ﻻ ﺗﻘﻠق. ﺑﺑﺳﺎطﺔ اﺗرك ﺗﻠك اﻟﺟرﻋﺔ ﺗﻣﺎﻣًﺎ. ﺛم ﺗﻧﺎول ﺟرﻋﺗك اﻟﺗﺎﻟﯾﺔ ﻓﻲ اﻟوﻗت اﻟﻣﻧﺎﺳب. ﻻ ﺗﺄﺧذ ﺟرﻋﺔ ﻣﺿﺎﻋﻔﺔ ﻟﺗﻌوﯾض اﻟﺟرﻋﺔ اﻟﻣﻧﺳﯾﺔ.</p><p dir="RTL">إذا ﻛﺎن ﻟدﯾك أي أﺳﺋﻠﺔ أﺧرى ﺣول اﺳﺗﺧدام ھذا اﻟدواء ، اﺳﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع. ﯾﻣﻛن ﻟﺟﻣﯾﻊ اﻷدوﯾﺔ أن ﺗﺳﺑب ردود ﻓﻌل ﺗﺣﺳﺳﯾﺔ ﻋﻠﻰ اﻟرﻏم ﻣن ﻧدرة ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ اﻟﺧطﯾرة. اﻷﻋراض اﻟﺗﺎﻟﯾﺔ ھﻲ اﻟﻌﻼﻣﺎت اﻷوﻟﻰ ﻟﻣﺛل ھذه اﻟﺗﻔﺎﻋﻼت:</p><p dir="RTL">&middot; أي أزﯾز ﻣﻔﺎﺟﺊ أو ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس أو دوار أو اﻧﺗﻔﺎخ ﻓﻲ اﻟﺟﻔون أو الوجه أو اﻟﺷﻔﺗﯾن أو اﻟﺣﻠق.</p><p dir="RTL">&middot; ﺗﻘﺷﯾر وﺑﺛور ﻓﻲ اﻟﺟﻠد واﻟﻔم واﻟﻌﯾﻧﯾن واﻷﻋﺿﺎء اﻟﺗﻧﺎﺳﻠﯾﺔ.</p><p dir="RTL">&middot; اﻟطﻔﺢ اﻟﺟﻠدي اﻟذي ﯾؤﺛر ﻋﻠﻰ اﻟﺟﺳم كله.</p><p dir="RTL">إذا ظﮭرت ﻟدﯾك أي ﻣن ھذه اﻷﻋراض أﺛﻧﺎء اﻟﻌﻼج ، ﯾﺟب ﻋﻠﯾك اﻟﺗوﻗف ﻋن ﺗﻧﺎول اﻟﻛﺑﺳوﻻت واﻻﺗﺻﺎل ﺑطﺑﯾﺑك ﻋﻠﻰ اﻟﻔور.</p><p dir="RTL">ﻗد ﺗﻌﺎﻧﻲ ﻣن ﻧوﺑﺔ ﺣﺎدة ﻣن زرق اﻟﻌﯾن. إذا ﻛﻧت ﺗرى ﺣﻠﻘﺎت ﻣﻠوﻧﺔ ﺣول اﻷﺿواء أو إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن أﻟم ﺷدﯾد ﻓﻲ أي ﻣن اﻟﻌﯾﻧﯾن وﺣوﻟﮭﺎ، ﻓﯾﺟب ﻋﻠﯾك طﻠب اﻟﻌﻧﺎﯾﺔ اﻟطﺑﯾﺔ ﻋﻠﻰ وجه اﻟﺳرﻋﺔ.</p><p dir="RTL">ﺗم رﺻد اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﺎﻟﯾﺔ:</p><p dir="RTL"><strong>شائعة ﺟدًا (ﻗد ﯾﺻﯾب أﻛﺛر ﻣن 1 ﻣن ﻛل10&nbsp; أﺷﺧﺎص).</strong></p><p dir="RTL">ﻓم ﺟﺎف</p><p dir="RTL"><strong>ﺷﺎﺋﻌﺔ (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ1&nbsp; ﻣن ﻛل10&nbsp; أﺷﺧﺎص).</strong></p><p dir="RTL">ﺧﻠل ﻓﻲ اﻟرؤﯾﺔ وﺻﻌوﺑﺔ ﻓﻲ اﻟﺗرﻛﯾز ، إرھﺎق ، ﺻداع ، آﻻم ﻓﻲ اﻟﺑطن ، ﻋﺳر ھﺿم ، إﻣﺳﺎك.</p><p dir="RTL"><strong>ﻏﯾر ﺷﺎﺋﻌﺔ (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ 1 ﻣن ﻛل 100 ﺷﺧص)</strong></p><p dir="RTL">اﻟﺷﻌور ﺑﺎﻟﻐﺛﯾﺎن واﻟﻘﻲء ، واﻟدوﺧﺔ ، واﻻرﺗﺟﺎف ، وﻋدم اﻟﻘدرة ﻋﻠﻰ إﻓراغ اﻟﻣﺛﺎﻧﺔ (اﺣﺗﺑﺎس اﻟﺑول)، واﺣﻣرار ، وﺗﻐﯾر ﻓﻲ ﺣﺎﺳﺔ اﻟﺗذوق ، واﻧﺧﻔﺎض ﺿﻐط اﻟدم ﻣﻊ اﻟﻧﻌﺎس ، واﻟﺣﻛﺔ ، وﺻﻌوﺑﺔ اﻟﺗﺑول.</p><p dir="RTL"><strong>ﻧﺎدرة (ﻗد ﺗظﮭر ﻟدى ﺣﺗﻰ1&nbsp; ﻣن ﻛل1000&nbsp; ﺷﺧص)</strong></p><p dir="RTL">طﻔﺢ ﺟﻠدي.</p><p dir="RTL">ﺳرﻋﺔ ﺿرﺑﺎت اﻟﻘﻠب.</p><p dir="RTL"><strong>ﻧﺎدر ﺟدًا (ﻗد ﯾؤﺛر ﻋﻠﻰ ﺷﺧص واﺣد ﻣن ﺑﯾن10000&nbsp; ﺷﺧص)</strong></p><p dir="RTL">اﻟﺷﻌور ﺑﺿرﺑﺎت ﻗﻠﺑك واﻷرق واﻻرﺗﺑﺎك.</p><p dir="RTL"><strong>غير ﻣﻌروف (ﻻ ﯾﻣﻛن ﺗﻘدﯾر اﻟﺗردد ﻣن اﻟﺑﯾﺎﻧﺎت اﻟﻣﺗﺎﺣﺔ)</strong></p><p dir="RTL">اﻹﺣﺳﺎس ﺑﺄﺷﯾﺎء ﻏﯾر ﺣﻘﯾﻘﯾﺔ (ھﻠوﺳﺔ).</p><p dir="RTL">اﺿطراب اﻟﻛﻼم</p><p dir="RTL"><strong>أعراض جانبیة إضافیة لدى الأطفال والمراھقین</strong></p><p dir="RTL">&nbsp;بالإضافة إلى ذلك ، في الدراسات التي أجریت على الأطفال لوحظت الآثار غیر المرغوب فیھا التالیة: فقدان الشھیة ، واضطراب النوم ، وضعف التركیز.</p><p dir="RTL">ﺟﻣﯾﻊ اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺣﺗﻣﻠﺔ ﻋﺎﺑرة وﺗﺗﻼﺷﻰ ﺑﻌد ﺗﻘﻠﯾل اﻟﺟرﻋﺔ أو إﻧﮭﺎء اﻟﻌﻼج ﺑﻌد&nbsp; 1-4 أﯾﺎم ﻛﺣد أﻗﺻﻰ. أﺛﻧﺎء اﻟﻌﻼج طوﯾل اﻷﻣد ، ﯾﺟب ﻣراﻗﺑﺔ إﻧزﯾﻣﺎت اﻟﻛﺑد ، ﻷن اﻟﺗﻐﯾرات اﻟﻌﻛﺳﯾﺔ ﻓﻲ إﻧزﯾﻣﺎت اﻟﻛﺑد ﻗد ﺗﺣدث ﻓﻲ ﺣﺎﻻت ﻧﺎدرة.</p><p dir="RTL">&nbsp;إذا ظﮭرت ﻟدﯾك أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ، ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ. ﯾﺗﺿﻣن ذﻟك أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣﺣﺗﻣﻠﺔ&nbsp; ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة. ﯾﺟب اﻹﺑﻼغ ﻋن أي ﺣدث ﻣﺷﺗﺑﮫ ﺑﮫ أو ﺳﻠﺑﻲ ﻋﻠﻰ ھذا اﻟﻣﻧﺗﺞ إﻟﻰ Drugsafety@labatec.com</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أوالصيدلي<strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot; احفظ ھذا اﻟدواء ﺑﻌﯾدًا ﻋن ﻣﺗﻧﺎول اﻷطﻔﺎل</p><p dir="RTL">&middot; ﻻ ﯾﺟوز ﺗﺧزﯾن اﻟﻌﺑوة ﻓوق 30 درﺟﺔ ﻣﺋوﯾﺔ.</p><p dir="RTL">&middot; ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣدون ﻋﻠﻰ اﻟﻛرﺗون.</p><p dir="RTL">&middot; يشير ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ اﻟﯾوم اﻷﺧﯾر ﻣن ﻧﻔس اﻟﺷﮭر.</p><p dir="RTL">&middot; ﻻ ﺗﺗﺧﻠص ﻣن اﻷدوﯾﺔ ﻓﻲ ﻣﯾﺎه اﻟﺻرف اﻟﺻﺣﻲ أو اﻟﻧﻔﺎﯾﺎت اﻟﻣﻧزﻟﯾﺔ.</p><p dir="RTL">&middot; اﺳﺄل اﻟﺻﯾدﻟﻲ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺗﺳﺗﺧدﻣﮭﺎ.</p><p dir="RTL">&middot; ﺳﺗﺳﺎﻋد ھذه اﻹﺟراءات ﻓﻲ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﺑروﺑﯾﻔرﯾن ھﯾدروﻛﻠورﯾد. يحتوي ﻛل قرص مغلف ﻋﻠﻰ 5 ﻣﻠﻎ ﻣن ﺑروﺑﯾﻔرﯾن ھﯾدروﻛﻠورﯾد.</p><p dir="RTL">اﻟﻣﻛوﻧﺎت اﻷﺧرى ھﻲ: مونوھیدرات اللاكتوز، مسحوق السلیلوز، ستیرات المغنیسیوم، السكروز، التلك، الكاولین الثقیل، كربونات الكالسیوم، ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم (E171)، صمغ الأكاسیا، السیلیكا الغرویة اللامائیة، ماكروغول &nbsp;6000 مونوھیدرات الجلوكوز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺗوﻓر ﻓﻲ اﻟﺻﯾدﻟﯾﺎت ﺑوﺻﻔﺔ طﺑﯾﺔ.</p><p dir="RTL">(ميكتونورم 5 ملغ) هي أقراص بيضاء مغلفة وهي ﻣﺗوﻓرة ﻓﻲ ﻋﻠب &nbsp;كرتون ذات 7 ( 7 أقراص &times; 1) و 28 ( 14 قرص &times; 2) قرصاً مغلفاً.</p><p dir="RTL">قد لا یتم تسویق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جهة التصنيع:</p><p dir="RTL">روتندوورف فارما ج م ب اتش - أﻟﻣﺎﻧﯾﺎ</p><p dir="RTL">جهة تحرير التشغيلات:</p><p dir="RTL">أﺑوﺟﯾﻔﺎ أرزﯾﻧﻣﺗﯾل - أﻟﻣﺎﻧﯾﺎ</p><p dir="RTL">صاحب ترخيص التسويق:</p><p dir="RTL">لاباتيك فارما أس أي، ميرين 1217 (جنيف)، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mictonorm 5 mg coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each coated tablet contains 5 mg propiverine hydrochloride (equivalent to 4.55 mg propiverine).

Excipients with known effect: Lactose monohydrate (34 mg), glucose monohydrate (0.31 mg) and sucrose (24.5 mg)
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet 
White in colour, lenticular in shape
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder or neurogenic detrusor overactivity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Coated tablets for oral use</p><p>&nbsp;</p><p>Recommended daily doses:</p><p>&nbsp;</p><p>Paediatric population: daily average of 0.8&nbsp;mg/kg body weight in two to three single doses</p><p>&nbsp;</p><p>Posology</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Body weight (kg)</p></td><td style="vertical-align:top"><p>Mictonorm 5&nbsp;mg per day</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;&ndash; 16</p></td><td style="vertical-align:top"><p>1&nbsp;&ndash; 0&nbsp;- 1</p></td></tr><tr><td style="vertical-align:top"><p>17&nbsp;&ndash; 22</p></td><td style="vertical-align:top"><p>1&nbsp;&ndash; 1&nbsp;- 1</p></td></tr><tr><td style="vertical-align:top"><p>23&nbsp;&ndash; 28</p></td><td style="vertical-align:top"><p>2&nbsp;&ndash; 0&nbsp;&ndash; 2</p></td></tr><tr><td style="vertical-align:top"><p>29&nbsp;&ndash; 34</p></td><td style="vertical-align:top"><p>2&nbsp;&ndash; 1&nbsp;- 2</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 35</p></td><td style="vertical-align:top"><p>2&nbsp;&ndash; 2&nbsp;&ndash; 2</p><p>or 3&nbsp;&ndash; 0&nbsp;&ndash; 3</p></td></tr></tbody></table><p>&nbsp;</p><p>In children with a body weight &ge; 35&nbsp;kg, the maximum dose is the same as the standard dose in adults of 15&nbsp;mg twice daily (2&nbsp;x 3&nbsp;Mictonorm 5&nbsp;mg).</p><p>Treatment of overactive bladder should not start before 5&nbsp;years of age, as organic development is still not complete in many cases. However, treatment of neurogenic detrusor overactivity due to spinal cord injuries can be started even before 5&nbsp;years of age. Administration of propiverine hydrochloride to children below 1&nbsp;year of age is not recommended due to a lack of data.</p><p>Treatment of children should be administered only within the framework of an overall therapeutic approach (e.g. so-called &ldquo;urotherapy&rdquo; in cases of idiopathic detrusor overactivity).</p><p>Due to the low active substance content, Mictonorm 5&nbsp;mg is mainly used in infancy or in adults with a low body weight.</p><p>&nbsp;</p><p>Adults: As a standard dose, 15&nbsp;mg propiverine hydrochloride twice daily is recommended; an increase to three times daily is possible. Some patients may respond to a dose as low as 15&nbsp;mg daily (3&nbsp;x 5&nbsp;mg).</p><p>For neurogenic detrusor overactivity, a dose of 15&nbsp;mg propiverine hydrochloride three times daily is recommended. The maximum recommended daily dose is 45&nbsp;mg.</p><p>&nbsp;</p><p>Elderly: Generally there is no special posology for the elderly (see section 5.2).</p><p>&nbsp;</p><p>Caution should be exercised and physicians should monitor patients carefully for side effects in the following dispositions (see sections 4.4, 4.5):</p><p>&nbsp;</p><p>Use in renal impairment: In patients with mild or moderate impairment of renal function, no dose adjustment is required; however, they should be treated with caution. In patients with severely impaired renal function (creatinine clearance &lt; 30&nbsp;ml/min), the maximum daily dose is 30&nbsp;mg.</p><p>&nbsp;</p><p>Use in hepatic impairment: In patients with mildly impaired hepatic function, there is no need for dose adjustment; however, treatment should proceed with caution. No studies have been performed to investigate the use of propiverine in patients with moderately or severely impaired hepatic function. Its use is therefore not recommended in these patients.</p><p>&nbsp;</p><p>A high fat meal increases the bioavailability of propiverine. Therefore, propiverine should be taken before meals, especially in patients with renal or hepatic impairment (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mictonorm 5 mg is contraindicated in patients who have demonstrated hypersensitivity to the active substance or to any of the excipients and in patients suffering from one of the following disorders:
-	obstruction of the bowel
-	significant degree of bladder outflow obstruction where urinary retention may be anticipated
-	myasthenia gravis
-	intestinal atony
-	severe ulcerative colitis
-	toxic megacolon
-	uncontrolled angle closure glaucoma
-	moderate or severe hepatic impairment
-	tachyarrhythmias
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The medicinal product should be used with caution in patients suffering from:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autonomic neuropathy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment (see section 4.2)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p>Symptoms of the following diseases may be aggravated following administration of the medicinal product:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe congestive heart failure (NYHA IV)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prostatic enlargement</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiatus hernia with reflux oesophagitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac arrhythmia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tachycardia</p><p>&nbsp;</p><p>Propiverine, like other anticholinergics, induces mydriasis. Therefore, the risk to induce acute angle-closure glaucoma in individuals predisposed with narrow angles of the anterior chamber may be increased. Active substances of this class, including propiverine, have been reported to induce or precipitate acute angle-closure glaucoma.</p><p>&nbsp;</p><p>Pollakiuria and nocturia due to renal disease or congestive heart failure, as well as organic bladder diseases (e.g. urinary tract infections, malignancy), should be ruled out prior to treatment.</p><p>&nbsp;</p><p>In patients receiving active substances that are potent flavin-containing monooxygenase (FMO) inhibitors such as methimazole in combination with potent CYP 3A4/5 inhibitors (e.g. ketoconazole) treatment should start with the lowest recommended dose. The dose may thereafter be titrated to a higher dose. However, caution should be exercised and physicians should monitor these patients carefully for side effects (see sections 4.5, 5.2).</p><p>&nbsp;</p><p>This product contains glucose monohydrate, lactose monohydrate and sucrose.&nbsp;</p><p>Glucose monohydrate:</p><p>Patients with rare glucose-galactose malabsorption should not take this medicine.</p><p>Lactose monohydrate:</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Sucrose:</p><p>Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p>&nbsp;</p><p>Mictonorm 5&nbsp;mg is gluten free</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased effects due to concomitant treatment with tricyclic antidepressants (e. g. imipramine), tranquillisers (e.g. benzodiazepines), anticholinergics (if applied systemically), amantadine, neuroleptics (e. g. phenothiazines) and beta-adrenoceptor agonists (beta-sympathomimetics).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased effects due to concomitant treatment with cholinergic medicinal products.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced blood pressure in patients treated with isoniazid.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The effect of prokinetics such as metoclopramide may be decreased.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic interactions are possible with other active substances metabolised by cytochrome P450 3A4 (CYP 3A4). However, a very pronounced increase of concentrations for such active substances is not expected as the effects of propiverine are small compared to classical enzyme inhibitors (e.g. ketoconazole or grapefruit juice). Propiverine may be considered as weak inhibitor of CYP 3A4. Pharmacokinetic studies with patients concomitantly receiving potent CYP 3A4 inhibitors such as azole antifungals (e.g. ketoconazole, itraconazole) or macrolide antibiotics (e.g. erythromycin, clarithromycin) have not been performed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients receiving concomitant treatment with active substances that are potent inhibitors of CYP 3A4 combined with methimazole:<br />In patients receiving active substancesthat are potent flavin-containing monooxygenase (FMO) inhibitors such as methimazole in combination with potent CYP 3A4/5 inhibitors treatment should start with the lowest recommended dose. The dose may thereafter be titrated to a higher dose. However, caution should be exercised and physicians should monitor these patients carefully for side effects (see sections 4.4, 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no data from the use of propiverine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Propiverine is not recommended during pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>It is unknown whether propiverine or metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of propiverine or metabolites in milk. A risk to the newborn or infant cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from propiverine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p>Fertility</p><p>There are no human data on the effect of propiverine on fertility.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>Propiverine may produce drowsiness and blurred vision. This may impair the patient&#39;s ability to exert activities that require mental alertness such as operating a motor vehicle or other machinery, or to exert hazardous work while taking this medicinal product.</p><p>Sedative active substances may enhance the drowsiness caused by propiverine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Within each system organ class, the undesirable effects are ranked under heading of frequency using the following convention:</p><p>Very common&nbsp;&nbsp; (&ge; 1/10)</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/100&nbsp;to &lt; 1/10)</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/1,000&nbsp;to &lt; 1/100)</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/10,000&nbsp;to &lt; 1/1,000)</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt; 1/10,000)</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (cannot be estimated from the available data).</p><p>&nbsp;</p><p>All undesirable effects are transient and recede after a dose reduction or termination of the therapy after maximum 1-4 days.</p><p>&nbsp;</p><p>Immune system disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity</p><p>&nbsp;</p><p>Psychiatric disorders</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness, confusion</p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucination</p><p>&nbsp;</p><p>Nervous system disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor, dizziness, dysgeusia</p><p>Not known: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech disorder</p><p>&nbsp;</p><p>Eye disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accommodation disorder, visual impairment</p><p>&nbsp;</p><p>Cardiac disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tachycardia</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitation</p><p>&nbsp;</p><p>Vascular disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood pressure with drowsiness, flushing</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, abdominal pain, dyspepsia</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea/vomiting</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pruritus</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary retention, bladder and urethral symptoms</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&nbsp;</p><p>Paediatric population</p><p>In studies with children, the following undesirable effects have been reported in addition: decreased appetite, sleep disorder and disturbance in attention.</p><p>&nbsp;</p><p>During long-term therapy hepatic enzymes should be monitored, because reversible changes of liver enzymes might occur in rare cases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms:</p><p>Overdose with the muscarinic receptor antagonist propiverine can potentially result in severe anticholinergic effects. Peripheral and central nervous system disturbances may occur, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bradycardia, possibly leading to tachycardia in the further course</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mydriasis and accommodation disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary retention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhibition of intestinal motility</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness, confusion, hallucination, confabulation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, nausea, speech disorder, muscular weakness</p><p>&nbsp;</p><p>Treatment:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of overdose with propiverine the patient should be treated with activated charcoal suspension with plenty amount of water.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastric lavage should only be taken into consideration with protective intubation, use of an oiled tube (dryness of mucosa) and if performed within 1 hour after ingestion of propiverine. Vomiting must not be induced.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forced diuresis or hemodialysis is not effective to enhance the renal elimination.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case of severe central anticholinergic effects such as hallucinations or pronounced excitation antidote treatment with physostigmine can be attempted.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion or pronounced excitation: treatment with benzodiazepines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory insufficiency: treatment with artificial respiration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary retention: treatment with catheterization</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mydriasis: treatment with pilocarpine eye drops and/or darkening of the patient&rsquo;s room</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: G04B D06</p><p>Pharmacotherapeutic group: Urologicals, drugs for urinary frequency and incontinence</p><p>&nbsp;</p><p>Mechanism of action</p><p>Inhibition of calcium influx and modulation of intracellular calcium in the urinary bladder smooth muscle cells causing musculotropic spasmolysis.</p><p>Inhibition of the efferent connection of the nervus pelvicus due to anticholinergic action.</p><p>&nbsp;</p><p>Pharmacodynamic effects</p><p>In animal models propiverine hydrochloride causes a dose-dependent decrease of the intravesical pressure and an increase in bladder capacity.</p><p>The effect is based on the sum of the pharmacological properties of propiverine and three active urinary metabolites as shown in isolated detrusor strips of human and animal origin.</p><p>&nbsp;</p><p>Paediatric population</p><p>In a randomised, placebo-controlled, double-blind phase-III study, significant efficacy (decrease in incontinence episodes and voiding frequency, increase in voided volume) was demonstrated for propiverine in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following information refers to a formulation containing 15&nbsp;mg propiverine hydrochloride.</p><p>&nbsp;</p><p>General characteristics of the active substance</p><p>Propiverine is nearly completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Effects on urinary bladder smooth muscle cells are due to the parent compound and three active metabolites as well, which are rapidly excreted into the urine.</p><p>&nbsp;</p><p>Absorption</p><p>After oral administration of Propiverine hydrochloride 15&nbsp;mg, propiverine is rapidly absorbed from the gastrointestinal tract with maximal plasma concentrations reached after 2.3&nbsp;hours.</p><p>The mean absolute bioavailability of Propiverine hydrochloride 15&nbsp;mg is 40.5% (arithmetic mean value of AUC<sub>0-</sub><sub>&yen;</sub> (p.o.) / AUC<sub>0-</sub><sub>&yen;</sub> (i.v.)).</p><p>&nbsp;</p><p>Food intake increases the bioavailability of propiverine (mean increase 1.3-fold), but does not significantly affect the maximum plasma concentrations of propiverine or its main metabolite propiverine-N-oxide. This difference in bioavailability is unlikely to be of clinical significance but adjustment of dose in relation to food intake could be required in patients suffering from impaired renal or hepatic function. Therefore, a regular intake before meals is recommended.</p><p>&nbsp;</p><p>Distribution</p><p>After administration of Propiverine hydrochloride 15&nbsp;mg t. i. d., steady state is reached after four to five days at a higher concentration level than after single dose application (C<sub>average</sub> = 61&nbsp;ng/ml).</p><p>The volume of distribution was estimated in 21&nbsp;healthy volunteers after intravenous administration of propiverine hydrochloride to range from 125&nbsp;to 473&nbsp;l (mean 279&nbsp;l) indicating that a large amount of available propiverine is distributed to peripheral compartments. The binding to plasma proteins is 90&nbsp;- 95% for the parent compound and about 60% for the main metabolite.</p><p>&nbsp;</p><p>&nbsp;</p><p>Plasma concentrations of propiverine in 16&nbsp;healthy volunteers after single and repeated administration of Propiverine hydrochloride 15&nbsp;mg (t. i. d. for 6&nbsp;days):</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Grafik_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:81.6pt;
  margin-top:-12.7pt;width:387.1pt;height:147.5pt;z-index:251658752;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
  mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
  mso-height-relative:margin' o:allowoverlap="f">
  <v:imagedata src="file:///C:\Users\smohammadi\AppData\Local\Packages\oice_15_974fa576_32c1d314_8a\AC\Temp\msohtmlclip1\01\clip_image001.wmz"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
  <w:anchorlock/>
 </v:shape><![endif]--></p><p><img src="data:image/png;base64,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" alt="" width="900" height="343" vspace="0" hspace="0" border="0" style="width:900px;height:343px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;<p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Steady state characteristics of propiverine following multiple-dose administration to 16 healthy volunteers of Propiverine hydrochloride 15&nbsp;mg (t.i.d. for 6 days):</p></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose interval</p></td><td colspan="2" style="vertical-align:top"><p>AUC<sub>0-</sub><sub>t</sub></p></td><td colspan="2" style="vertical-align:top"><p>PTF</p></td><td colspan="2" style="vertical-align:top"><p>C<sub>average</sub></p></td></tr><tr><td style="vertical-align:top"><p>[h]</p></td><td style="vertical-align:top"><p>[ng&times;h/ml]</p></td><td style="vertical-align:top"><p>CV [%]</p></td><td style="vertical-align:top"><p>[%]</p></td><td style="vertical-align:top"><p>CV [%]</p></td><td style="vertical-align:top"><p>[ng/ml]</p></td><td style="vertical-align:top"><p>CV [%]</p></td></tr><tr><td style="vertical-align:top"><p>0&nbsp;- 8&nbsp;</p></td><td style="vertical-align:top"><p>515</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>8&nbsp;- 16&nbsp;</p></td><td style="vertical-align:top"><p>460</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>16&nbsp;- 24&nbsp;</p></td><td style="vertical-align:top"><p>421</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>&nbsp; CV: coefficient of variation</p><p>PTF: peak-trough fluctuation</p></td></tr></tbody></table><p>&nbsp;</p><p>Biotransformation</p><p>Propiverine is extensively metabolised by intestinal and hepatic enzymes. The primary metabolic route involves the oxidation of the piperidyl-N and is mediated via CYP 3A4&nbsp;and flavin monooxygenases (FMO) 1&nbsp;and 3 and leads to the formation of the much less active N-oxide, the plasma concentration of which greatly exceeds that of the parent substance. Four metabolites were identified in urine, three of them are pharmacologically active and may contribute to the therapeutic efficacy of propiverine.</p><p>In vitro there is a slight inhibition of CYP 3A4 and CYP 2D6 detectable which occurs at concentrations exceeding therapeutic plasma concentrations 10- to 100-fold (see section 4.5).</p><p>&nbsp;</p><p>Elimination</p><p>Following administration of 30&nbsp;mg oral dose of <sup>14</sup>C-propiverine hydrochloride to healthy volunteers, 60% of the radioactivity was recovered in urine and 21% was recovered in faeces within 12&nbsp;days. Less than 1% of an oral dose is excreted unchanged in the urine. Mean total clearance after single dose administration of 30&nbsp;mg is 371&nbsp;ml/min (191&nbsp;- 870&nbsp;ml/min).</p><p>In three studies including a total of 37&nbsp;healthy volunteers mean elimination half-life was 14.1, 20.1&nbsp;and 22.1&nbsp;hours, respectively.</p><p>&nbsp;</p><p>Linearity/non-linearity</p><p>Pharmacokinetic parameters of propiverine and propiverine-N-oxide following oral administration of 10&nbsp;&ndash; 30&nbsp;mg of propiverine hydrochloride are linearly related to dose.</p><p>There are no changes of pharmacokinetics during steady state compared to single dose administration.</p><p>&nbsp;</p><p>Characteristics in patients</p><p>Renal impairment:</p><p>Severe renal impairment does not significantly alter the disposition of propiverine and its main metabolite, propiverine-N-oxide, as deduced from a single dose study in 12 patients with creatinine clearance &lt; 30 ml/min. No dose adjustment is to be recommended as long as the total daily dose does not exceed 30&nbsp;mg propiverine hydrochloride. In case that higher dose shall be administered a careful titration of dose is recommended considering anticholinergic effects as a marker for tolerability.</p><p>&nbsp;</p><p>Hepatic insufficiency</p><p>There were similar steady state pharmacokinetics in 12 patients with mild to moderate impairment of liver function due to fatty liver disease as compared to 12 healthy controls. No data are available for severe hepatic impairment.</p><p>&nbsp;</p><p>Age</p><p>The comparison of trough plasma concentrations during steady state (Propiverine hydrochloride 15&nbsp;mg t. i. d. for 28&nbsp;days) reveals no difference between older patients (60&nbsp;&ndash; 85&nbsp;years; mean 68) and young healthy subjects. The ratio of parent active substances to metabolite remains unchanged in older patients indicating the metabolic conversion of propiverine to its main metabolite, propiverine-N-oxide, not to be an age-related or limiting step in the overall excretion.</p><p>&nbsp;</p><p>Paediatric population</p><p>A dose-escalation study in children demonstrated a balanced relationship between efficacy and tolerability for the mean dose of 0.8 mg/kg body weight/per day. Up to the recommended dose range, the pharmacokinetic properties (e.g. AUC<sub>0-8</sub>, C<sub>max</sub>, C<sub>av</sub>) are dose-proportional. After administration of a twice-daily dose of 0.4&nbsp;mg/kg body weight, serum levels in children aged 5&nbsp;to 10&nbsp;years reach approximately the same values as after administration of the therapeutic dose of 15&nbsp;mg propiverine hydrochloride twice daily in adults.</p><p>&nbsp;</p><p>Patients with glaucoma</p><p>Intraocular pressure in patients with open angle glaucoma and in patients with treated (controlled) angle closure glaucoma is not increased by Propiverine hydrochloride 15&nbsp;mg t.i.d. treatment for 7 days, as demonstrated by two placebo-controlled studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In long-term oral dose studies in two mammalian species the main treatment-related effect were changes in the liver (including elevation of hepatic enzymes). These were characterised by hepatic hypertrophy and fatty degeneration. The fatty degeneration was reversible upon cessation of treatment.</p><p>No effects on male and female fertility and reproduction behaviour were observed in toxicological studies with rats.</p><p>In animal studies, skeletal retardation in the offspring occurred when the active substance was administered orally at high doses to pregnant females. In lactating mammals propiverine was excreted into the milk.</p><p>There was no evidence of mutagenicity. The carcinogenicity study in mice demonstrated an increased incidence of hepatocellular adenoma and carcinoma in high dose males. In the rat carcinogenicity study hepatocellular adenoma, kidney adenoma and urinary bladder papilloma has been demonstrated in high dose male rats, while in female animals endometrial stromal polyps were increased at the high dose levels. Both the rat and mouse tumours were considered to be species-specific and therefore not of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>lactose monohydrate,</p><p>cellulose, powdered,</p><p>magnesium stearate</p><p>&nbsp;</p><p>Tablet coat:</p><p>calcium carbonate,</p><p>glucose monohydrate,</p><p>acacia gum,</p><p>macrogol 6000,</p><p>sucrose,</p><p>silica, colloidal anhydrous,</p><p>talc,</p><p>titanium dioxide (E171),</p><p>kaolin, heavy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of sight and reach of children</p><p>Do not store the blister pack above 30&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC/aluminium blisters in boxes of 7, 28 coated tablets.</p><p>&nbsp;</p><p>Not all package sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Labatec Pharma SA, 1217 Meyrin (Geneva), Switzerland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>